BXCL 501

Drug Profile

BXCL 501

Alternative Names: BXCL501

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inveni
  • Developer BioXcel Therapeutics
  • Class Anxiolytics; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Agitation

Most Recent Events

  • 03 Nov 2017 Phase-I clinical trials in Agitation in USA (Sublingual) prior to 03/11/2017 (BioXcel pipeline, November 2017)
  • 30 Apr 2017 BioXcel Therapeutics in-licenses BXCL 501 from Inveni (Inveni website, April 2017)
  • 17 Apr 2017 Preclinical trials in Agitation in USA (Sublingual) (BioXcel Corporation pipeline, April 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top